Akebia Therapeutics(AKBA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

AKBA Akebia Therapeutics

Pre-Mkt 01-21 06:24:20 EST

1.34

-0.02

-1.47%

High1.36	Low1.30	Vol2.46M
Open1.32	D1 Closing1.36	Amplitude4.41%
Mkt Cap355.59M	Tradable Cap348.13M	Total Shares265.37M
T/O3.29M	T/O Rate0.95%	Tradable Shares259.80M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"AKBA","market":"US","secType":"STK","nameCN":"Akebia Therapeutics","latestPrice":1.34,"timestamp":1768942800000,"preClose":1.36,"halted":0,"volume":2463427,"delay":0,"changeRate":-0.014705882352941188,"floatShares":259801013,"shares":265365993,"eps":-0.08,"marketStatus":"Pre-Mkt","change":-0.02,"latestTime":"01-21 06:24:20 EST","open":1.32,"high":1.36,"low":1.3,"amount":3287206.3498226,"amplitude":0.044118,"askPrice":1.5,"askSize":100,"bidPrice":1.22,"bidSize":200,"shortable":3,"etf":0,"ttmEps":-0.08,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1769005800000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":1395288000000,"exchange":"NASDAQ","adjPreClose":1.34,"postHourTrading":{"tag":"盘后","latestPrice":1.3303,"preClose":1.34,"latestTime":"19:57 EST","volume":12877,"amount":17213.5136,"timestamp":1768957056917,"change":-0.0097,"changeRate":-0.007239,"amplitude":0.007463},"volumeRatio":0.6225031224363279,"impliedVol":0.867,"impliedVolPercentile":0.472},"requestUrl":"/m/hq/s/AKBA/wiki","defaultTab":"wiki","newsList":[{"id":"2602487835","title":"Akebia Therapeutics Outlines 2026 Vafseo Strategy and Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2602487835","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602487835?lang=en_us&edition=fundamental","pubTime":"2026-01-12 21:37","pubTimestamp":1768225066,"startTime":"0","endTime":"0","summary":"The latest announcement is out from Akebia Therapeutics ( ($AKBA) ). On January 12, 2026, Akebia Therapeutics announced corporate updates and a 202...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/akebia-therapeutics-outlines-2026-vafseo-strategy-and-pipeline?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/akebia-therapeutics-outlines-2026-vafseo-strategy-and-pipeline?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AKBA","BK4139"],"gpt_icon":0},{"id":"2602551032","title":"BRIEF-Akebia Therapeutics Inc - Akb-097 Phase 2 Rare Kidney Disease Basket Trial Scheduled To Begin In 2H 2026 With Initial Data Expected In 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2602551032","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602551032?lang=en_us&edition=fundamental","pubTime":"2026-01-12 21:03","pubTimestamp":1768223039,"startTime":"0","endTime":"0","summary":"BRIEF-Akebia Therapeutics Inc - Akb-097 Phase 2 Rare Kidney Disease Basket Trial Scheduled To Begin In 2H 2026 With Initial Data Expected In 2027Jan 12 (Reuters) - Akebia Therapeutics Inc AKBA.O:AKEBI","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nFWN3YD0SS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AKBA"],"gpt_icon":0},{"id":"2602510546","title":"Akebia Therapeutics Reports Strong Vafseo Growth and Advances Rare Kidney Disease Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2602510546","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602510546?lang=en_us&edition=fundamental","pubTime":"2026-01-12 21:01","pubTimestamp":1768222870,"startTime":"0","endTime":"0","summary":"Akebia Therapeutics Inc. announced key corporate updates and its 2026 pipeline outlook. The company reported it is positioned to increase the depth of Vafseo  prescribing entering 2026, with access to approximately 275,000 patients. Akebia expects revenue growth to resume in the first quarter of 2026, driven by increased patient access and anticipated improvements in adherence and compliance. In its rare kidney disease pipeline, Akebia dosed the first patient in a Phase 2 clinical trial of Praliciguat for focal segmental glomerulosclerosis  in December 2025 and plans to evaluate the drug in other rare podocytopathies. The company also plans to initiate an open-label Phase 2 rare kidney disease basket trial in the second half of 2026, assessing indications such as IgA Nephropathy , Lupus Nephritis , and C3 Glomerulopathy , with initial data expected in 2027. Additionally, AKB-9090, a HIF-PH inhibitor, is scheduled to enter Phase 1 trials for acute kidney injury associated with cardiac s","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nNDL3wYbNV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","SG9999014013.SGD","BK4139","BK4112","LU2210149790.SGD","LU2095319765.USD","IE00B64PRP62.GBP","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","SG9999014005.SGD","BK4588","AKBA","LU0314104364.USD","SG9999014021.USD","BK4585","NDAQ","SG9999014039.USD","IE00BKPKM429.USD"],"gpt_icon":0},{"id":"2601813803","title":"Akebia Therapeutics Doses First Patient in Mid-Stage Study of Kidney Disease Drug Praliciguat","url":"https://stock-news.laohu8.com/highlight/detail?id=2601813803","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601813803?lang=en_us&edition=fundamental","pubTime":"2026-01-06 22:16","pubTimestamp":1767709009,"startTime":"0","endTime":"0","summary":"Akebia Therapeutics  said Tuesday it has dosed the first patient in a phase 2 trial of its experimental drug, praliciguat, for the treatment of a rare kidney disease.The company said the study will assess the safety and efficacy of the drug in about 60 adults with the condition who are already being treated with standard treatment.Akebia said the primary endpoint of the study is the change from baseline in the urine protein-to-creatinine ratio, a key marker of kidney damage. A key secondary endpoint is the percentage of patients achieving partial remission, the company added.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AKBA","SSI","BK4139"],"gpt_icon":0},{"id":"2601818114","title":"BRIEF-Akebia Therapeutics Announces First Patient Dosed In Phase 2 Clinical Trial Of Praliciguat","url":"https://stock-news.laohu8.com/highlight/detail?id=2601818114","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601818114?lang=en_us&edition=fundamental","pubTime":"2026-01-06 22:03","pubTimestamp":1767708212,"startTime":"0","endTime":"0","summary":"BRIEF-Akebia Therapeutics Announces First Patient Dosed In Phase 2 Clinical Trial Of Praliciguat Jan 6 (Reuters) - Akebia Therapeutics Inc AKBA.O:AKEBIA THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN P","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260106:nTUA2F1STP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AKBA"],"gpt_icon":0},{"id":"2601897502","title":"Akebia Therapeutics Doses First Patient in Phase 2 Trial of Praliciguat for FSGS","url":"https://stock-news.laohu8.com/highlight/detail?id=2601897502","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601897502?lang=en_us&edition=fundamental","pubTime":"2026-01-06 21:00","pubTimestamp":1767704435,"startTime":"0","endTime":"0","summary":"Akebia Therapeutics Inc. has announced the dosing of the first patient in a Phase 2 clinical trial evaluating praliciguat, an oral, once-daily soluble guanylate cyclase  stimulator, for the treatment of biopsy-confirmed focal segmental glomerulosclerosis , a rare kidney disease. The randomized, double-blind, placebo-controlled, multicenter study will enroll approximately 60 adults with FSGS who are already receiving maximally tolerated doses of an ACE inhibitor or angiotensin receptor blocker. The trial’s primary endpoint is the change from baseline in urine protein-to-creatinine ratio  at Week 24. A secondary endpoint will assess the percentage of patients achieving partial remission at Week 24. All participants will receive praliciguat during an additional 24-week open-label extension period. Study results have not yet been presented and will be provided in the future.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260106:nNDL6Xm0wt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014005.SGD","BK4112","BK4585","LU2210149790.SGD","SG9999014021.USD","BK4588","SG9999014013.SGD","IE00B64PRP62.GBP","LU2210150020.SGD","BK4139","LU0314104364.USD","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","LU2095319765.USD","NDAQ","IE00BKPKM429.USD","AKBA","SG9999014039.USD"],"gpt_icon":0},{"id":"2601897000","title":"Akebia Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of Praliciguat for the Treatment of Focal Segmental Glomerulosclerosis (FSGS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2601897000","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601897000?lang=en_us&edition=fundamental","pubTime":"2026-01-06 21:00","pubTimestamp":1767704400,"startTime":"0","endTime":"0","summary":"Clinical trial evaluating changes in urine protein-to-creatinine ratio, a widely-accepted endpoint measuring risk reduction of kidney failureCAMBRIDGE, Mass., Jan.  06, 2026  (GLOBE NEWSWIRE) -- Akebi","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/06/3213549/37519/en/Akebia-Therapeutics-Announces-First-Patient-Dosed-in-Phase-2-Clinical-Trial-of-Praliciguat-for-the-Treatment-of-Focal-Segmental-Glomerulosclerosis-FSGS.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARB","AKBA","BK4139","FSGS"],"gpt_icon":0},{"id":"2601837895","title":"Akebia Therapeutics Grants Stock Options to New Employee at $1.61 Per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2601837895","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601837895?lang=en_us&edition=fundamental","pubTime":"2026-01-06 05:05","pubTimestamp":1767647143,"startTime":"0","endTime":"0","summary":"Akebia Therapeutics Inc. has granted stock options to a newly hired employee, allowing the purchase of 197,900 shares of common stock at an exercise price of $1.61 per share, reflecting the closing price on the grant date of December 31, 2025. The options vest over four years, with 25% vesting after the first year and the remaining 75% vesting quarterly. Each option carries a 10-year term.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akebia Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on January 05, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nNDL6XLl18:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314104364.USD","IE00B64PRP62.GBP","NDAQ","LU2210150020.SGD","SG9999014039.USD","LU2210149790.SGD","BK4588","SG9999014005.SGD","AKBA","LU2095319765.USD","BK4585","IE00B3QW5Z07.USD","SG9999014021.USD","BK4139","SG9999014013.SGD","IE00BGHQF748.EUR","BK4112","IE00BKPKM429.USD"],"gpt_icon":0},{"id":"2601837937","title":"Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2601837937","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601837937?lang=en_us&edition=fundamental","pubTime":"2026-01-06 05:05","pubTimestamp":1767647100,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass., Jan.  05, 2026  (GLOBE NEWSWIRE) -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, g","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/05/3213185/37519/en/Akebia-Therapeutics-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AKBA"],"gpt_icon":0},{"id":"2588058336","title":"Akebia Therapeutics Price Target Maintained With a $6.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2588058336","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588058336?lang=en_us&edition=fundamental","pubTime":"2025-12-02 20:21","pubTimestamp":1764678060,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/AKBA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 02, 2025 07:21 ET (12:21 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AKBA"],"gpt_icon":0},{"id":"2588080467","title":"Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2588080467","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588080467?lang=en_us&edition=fundamental","pubTime":"2025-12-02 05:05","pubTimestamp":1764623100,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass., Dec.  01, 2025  (GLOBE NEWSWIRE) -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, g","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/01/3197426/37519/en/Akebia-Therapeutics-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AKBA"],"gpt_icon":0},{"id":"2588377769","title":"Top Midday Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2588377769","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588377769?lang=en_us&edition=fundamental","pubTime":"2025-12-02 02:32","pubTimestamp":1764613968,"startTime":"0","endTime":"0","summary":"Q32 Bio's  shares doubled amid heavy trading after the company said Monday it sold alopecia areata drug candidate ADX-097 to Akebia Therapeutics .More than 157.3 million shares of Q32 Bio traded intraday compared with a daily average of about 223,000.Kala Bio  said Monday it has entered into a $6 million securities purchase agreement with private investor David E. Lazar for the purchase of the company's non-voting convertible preferred stock.Effective immediately, Lazar has been appointed Kala's chief executive officer and chairman. Former CEO Todd Bazemore continues to serve on the board.Shares surged 58% as intraday trading volume catapulted to over 147.5 million from a daily average of about 1.7 million.Belite Bio  said Monday its phase 3 trial of Tinlarebant to treat Stargardt disease type 1 met its primary efficacy endpoint.Shares advanced 8.4% as intraday trading volume climbed to more than 611,000 from a daily average of about 90,000.Price: 4.40, Change: +2.21, Percent Change: +","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","AKBA","BK4007","BLTE","KALA","QTTB"],"gpt_icon":0},{"id":"2588577926","title":"Why Is Small-Cap Q32 Bio Stock Soaring On Monday?","url":"https://stock-news.laohu8.com/highlight/detail?id=2588577926","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588577926?lang=en_us&edition=fundamental","pubTime":"2025-12-01 22:43","pubTimestamp":1764600180,"startTime":"0","endTime":"0","summary":"Q32 Bio shares rise after selling ADX-097 to Akebia in a deal worth up to $592 million, boosting cash runway into late 2027.","market":"hk","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/12/01/Medical-Business-Handshake.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/12/01/Medical-Business-Handshake.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/health-care/25/12/49136089/why-is-small-cap-q32-bio-stock-soaring-on-monday","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/health-care/25/12/49136089/why-is-small-cap-q32-bio-stock-soaring-on-monday","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["AKBA","QTTB","BK4139"],"gpt_icon":0},{"id":"2588778401","title":"Akebia Therapeutics Sets Rare Kidney Drug Plan After Q32 Bio Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2588778401","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588778401?lang=en_us&edition=fundamental","pubTime":"2025-12-01 21:40","pubTimestamp":1764596454,"startTime":"0","endTime":"0","summary":"Akebia Therapeutics (AKBA) said Monday that it has built a rare kidney disease pipeline around a complement inhibitor acquired from Q32 Bio (QTTB) and an existing drug now in a mid-stage study for foc","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["QTTB","BK4139","AKBA"],"gpt_icon":0},{"id":"2588819778","title":"BRIEF-Akebia Announces Establishment Of Rare Kidney Disease Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2588819778","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588819778?lang=en_us&edition=fundamental","pubTime":"2025-12-01 21:21","pubTimestamp":1764595262,"startTime":"0","endTime":"0","summary":"BRIEF-Akebia Announces Establishment Of Rare Kidney Disease PipelineDec 1 (Reuters) - Akebia Therapeutics Inc AKBA.O:AKEBIA ANNOUNCES ESTABLISHMENT OF RARE KIDNEY DISEASE PIPELINEAKEBIA THERAPEUTICS: ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nTUA2STW5D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AKBA","QTTB","BK4139"],"gpt_icon":0},{"id":"2588720304","title":"BRIEF-Q32 Bio Sells Complement Inhibitor Adx-097","url":"https://stock-news.laohu8.com/highlight/detail?id=2588720304","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588720304?lang=en_us&edition=fundamental","pubTime":"2025-12-01 21:03","pubTimestamp":1764594181,"startTime":"0","endTime":"0","summary":"BRIEF-Q32 Bio Sells Complement Inhibitor Adx-097Dec 1  - Q32 BIO SELLS COMPLEMENT INHIBITOR ADX-097Q32 BIO INC - $12 MILLION PAYMENTS EXPECTED TO EXTEND CASH RUNWAY INTO SECOND HALF OF 2027Q32 BIO INC - ELIGIBLE FOR UP TO $592 MILLION INCLUDING ROYALTIESSource text: ID:nPn4S4bM2a ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nTUA5XFQDT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AKBA","QTTB","BK4139"],"gpt_icon":0},{"id":"2588727118","title":"Q32 Bio Sells Lead Product Candidate to Akebia Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2588727118","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588727118?lang=en_us&edition=fundamental","pubTime":"2025-12-01 20:46","pubTimestamp":1764593160,"startTime":"0","endTime":"0","summary":"Q32 Bio said it sold the lead product candidate from its tissue-targeted complement inhibitor platform to Akebia Therapeutics.The Waltham, Mass., biotech company said Monday it will receive $12 million in upfront payments and a near-term milestone. Q32 Bio said it will be eligible to receive a total of up to $592 million, pending the achievement of certain development, regulatory and commercial milestones, in addition to tiered royalties of up to a mid-teen percent of annual net sales.The transaction will strengthen the company's cash position, extending its runway into the second half of 2027, while also enabling it to focus on the advancement of bempikibart, its treatment for autoimmune and inflammatory diseases, Q32 Bio said.Shares of Q32 jumped 78% in premarket trading, to $3.90, while Akebia's stock was roughly flat.Akebia said the product candidate, AKB-097, is believed to have applicability across a wide range of complement-mediated rare kidney diseases.\"While our commercial and","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AKBA","QTTB","BK4139"],"gpt_icon":0},{"id":"2588119727","title":"Top Premarket Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2588119727","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588119727?lang=en_us&edition=fundamental","pubTime":"2025-12-01 20:45","pubTimestamp":1764593159,"startTime":"0","endTime":"0","summary":"Q32 Bio  shares were 71% higher pre-bell Monday after the company said it has sold alopecia areata drug candidate ADX-097 to Akebia Therapeutics .Belite Bio  stock was up 17% after the company said that a late-stage trial of Tinlarebant to treat Stargardt eye disease met its primary efficacy endpoint.Canadian Solar  shares were 13% higher after the company said it will resume direct oversight of its US operations.INVO Fertility  stock was up 12% after the company said it plans to acquire fertility clinic Family Beginnings.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BLTE","BK4585","BK4082","BK4588","IVF","QTTB","BK4141","BK4007","BK4519","AKBA","BK4139","BK4526"],"gpt_icon":1},{"id":"2588082724","title":"Akebia Therapeutics Acquires Global Rights to AKB-097 from Q32 Bio","url":"https://stock-news.laohu8.com/highlight/detail?id=2588082724","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588082724?lang=en_us&edition=fundamental","pubTime":"2025-12-01 20:00","pubTimestamp":1764590425,"startTime":"0","endTime":"0","summary":"Akebia Therapeutics Inc. announced the signing of an Asset Purchase Agreement with Q32 Bio, under which Akebia acquired global rights to Q32 Bio's ADX-097, now referred to as AKB-097. As part of the agreement, Akebia made an upfront payment of $7.0 million to Q32 Bio and will make an additional $3.0 million payment six months after the closing. The agreement also includes provisions for potential additional development, regulatory, and commercial milestone payments, as well as tiered royalties on annual net sales of AKB-097.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akebia Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on December 01, 2025, and is solely responsible for the inf","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nNDL1kPh8k:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","BK4112","QTTB","LU0314104364.USD","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","IE00BGHQF748.EUR","BK4588","BK4139","BK4585","IE00BKPKM429.USD","AKBA","LU2210150020.SGD","LU2095319765.USD","NDAQ"],"gpt_icon":0},{"id":"2588787724","title":"Akebia Announces Establishment of Rare Kidney Disease Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2588787724","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588787724?lang=en_us&edition=fundamental","pubTime":"2025-12-01 20:00","pubTimestamp":1764590403,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nTUA2STW5D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","AKBA","QTTB"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.akebia.com","stockEarnings":[{"period":"1week","weight":-0.029},{"period":"1month","weight":-0.1928},{"period":"3month","weight":-0.5518},{"period":"6month","weight":-0.651},{"period":"1year","weight":-0.3527},{"period":"ytd","weight":-0.1677}],"compareEarnings":[{"period":"1week","weight":-0.0233},{"period":"1month","weight":-0.0044},{"period":"3month","weight":0.0146},{"period":"6month","weight":0.068},{"period":"1year","weight":0.1339},{"period":"ytd","weight":-0.0064}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.416667,"avgChangeRate":0.003457},{"month":2,"riseRate":0.454545,"avgChangeRate":0.061016},{"month":3,"riseRate":0.454545,"avgChangeRate":-0.075459},{"month":4,"riseRate":0.5,"avgChangeRate":0.022435},{"month":5,"riseRate":0.583333,"avgChangeRate":0.042467},{"month":6,"riseRate":0.666667,"avgChangeRate":0.055123},{"month":7,"riseRate":0.5,"avgChangeRate":0.0412},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.035082},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.057186},{"month":10,"riseRate":0.083333,"avgChangeRate":-0.11772},{"month":11,"riseRate":0.666667,"avgChangeRate":0.130076},{"month":12,"riseRate":0.5,"avgChangeRate":0.078804}],"exchange":"NASDAQ","name":"Akebia Therapeutics","nameEN":"Akebia Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Akebia Therapeutics(AKBA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Akebia Therapeutics(AKBA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Akebia Therapeutics,AKBA,Akebia Therapeutics股票,Akebia Therapeutics股票老虎,Akebia Therapeutics股票老虎国际,Akebia Therapeutics行情,Akebia Therapeutics股票行情,Akebia Therapeutics股价,Akebia Therapeutics股市,Akebia Therapeutics股票价格,Akebia Therapeutics股票交易,Akebia Therapeutics股票购买,Akebia Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Akebia Therapeutics(AKBA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Akebia Therapeutics(AKBA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}